Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Classify Medical Fees into Doctors' and Hospitals' Fees
December 23, 2002
- Mevalotin's Patent Expiration Brings Sankyo No. 1 Issue
December 23, 2002
- SCN Group to Integrate Internet Services for Medical Professionals
December 23, 2002
- Fuso Extends Anticancer Gene Therapy Research Agreement with GenVec
December 23, 2002
- EPS Group Separates Its CRO and SMO Businesses
December 23, 2002
- Market for Health Foods Estimated to Be \1.4 Trillion
December 16, 2002
- Sales Up 3.3%, Net Profits Down 14.2% for 30 TSE-listed Companies
December 16, 2002
- HAC-Kimisawa to Place Top Priority on Profitability
December 16, 2002
- Sunstar: Consolidated Sales Down 3.8%
December 16, 2002
- OTC NEWS IN BRIEF
December 16, 2002
- EPS: Large Increases in Both Sales, Profits
December 16, 2002
- MEDICAL DEVICE NEWS IN BRIEF
December 16, 2002
- Nissan Chemical: Drug Sales Down 31.4% to \718 Mil.
December 16, 2002
- WORLD NEWS IN BRIEF
December 16, 2002
- Morishita Jintan: Sales Down 26.4% to \5.3 Bil.
December 16, 2002
- BULLETIN
December 16, 2002
- Biofermin: Sales Up 0.4% to \3,513 Mil.
December 16, 2002
- DIAGNOSTIC NEWS IN BRIEF
December 16, 2002
- JCR: Withdrawal of Application for IFN-a Affects Business Results
December 16, 2002
- Meet the Leaders (13)
December 16, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…